Autism and Mental Health: Understanding Co-Occurring Conditions

The CDC's 1 in 36 figure represents a significant increase from the 1 in 150 reported in 2000. This rise is primarily driven by expanded diagnostic criteria (DSM-5 consolidating Asperger's and PDD-NOS into the spectrum), increased clinician awareness, and better recognition of autism in populations historically overlooked — particularly women and AFAB (assigned female at birth) individuals.

The diagnostic gender gap is one of the most important and underaddressed issues in autism research. Historically, autism was described as a condition affecting boys at a 4:1 ratio. Current research suggests the actual ratio is closer to 3:1 — and the closer researchers look, the smaller the gap appears. The underdiagnosis of girls and women is not because autism presents differently biologically; it is because masking.

Masking — also called camouflaging — is the active suppression or concealment of autistic traits to appear neurotypical. Girls are socialized from early childhood to observe and mirror social behavior, to prioritize social harmony, and to perform relatability. These socialization pressures produce autistic girls who can maintain eye contact (through effortful mimicry), hold surface-level conversations (by scripting and rehearsing), and appear socially engaged — while experiencing profound internal distress, sensory overload, and exhaustion from the performance.

The consequence is late diagnosis — often not until adulthood, frequently not until the masking strategies collapse under the demands of a new job, a new relationship, or parenthood. Women and AFAB people are disproportionately represented among adults receiving first-time autism diagnoses in their 30s, 40s, and beyond. This late identification cycle carries significant mental health costs: decades of self-blame, misdiagnosis with conditions that share symptom overlap (BPD, bipolar disorder, treatment- resistant depression), and the toll of sustaining a performance that never fully fit.

Prior to DSM-5 (2013), autism and ADHD could not be co-diagnosed. DSM-IV required clinicians to choose one or the other — a rule that prevented accurate diagnosis of tens of thousands of people who clearly had both. DSM-5 removed this exclusion, and the co-occurrence data has been striking.

Studies find ADHD co-occurring in 30–80% of autistic people, depending on the sample and methodology. The most conservative estimates cluster around 30–50%; studies examining clinical populations or using dimensional assessments find higher rates. Conversely, 20–50% of people with ADHD meet criteria for autism.

The two conditions share executive function deficits — difficulties with working memory, task initiation, organization, cognitive flexibility, and impulse control — but through distinct mechanisms:

• ADHD executive dysfunction is primarily driven by dopaminergic deficiency in prefrontal circuits — the brain's motivation, focus, and inhibition networks. Stimulant medication directly targets this mechanism.
• Autism-related executive dysfunction involves broader differences in neural connectivity and processing — including in the anterior cingulate cortex, interoceptive networks, and the default mode network. It does not respond to stimulants in the same way, and stimulants may worsen rigidity or sensory sensitivity in some autistic people.

Clinically, AuDHD often presents as an especially complex picture: profound motivation deficits, intense hyperfocus in specific interest areas, significant social masking demands, and sensory sensitivities that make neurotypical environments acutely exhausting. Treatment requires accounting for both conditions — and understanding that they interact in ways that make simple protocols insufficient.

Anxiety (Up to 50%)

Anxiety is the most prevalent co-occurring condition in autism, affecting up to 50% of autistic individuals across multiple studies. The mechanisms are multiple and interact: sensory overload creates a direct physiological stress response, social unpredictability generates sustained anticipatory anxiety, the effort of masking and navigating a world not designed for autistic nervous systems is chronically activating, and interoception deficits mean autistic people often cannot accurately identify their own anxiety signals until they are in full physiological overload.

Anxiety in autism can present differently than in neurotypical people — more as meltdowns, shutdown, or rigid rule-following than as the verbal rumination typical in GAD. Misreading anxiety as “behavioral problems” or “noncompliance” is common in non-affirming clinical settings.

Depression

Depression affects approximately 40% of autistic adults. Importantly, depression in autistic people is often reactive — a consequence of chronic social exclusion, late diagnosis and its attendant grief, masking exhaustion, employment and relationship difficulties, and the experience of navigating a world that consistently communicates that the way you naturally exist is wrong. Treating the depression without addressing these structural causes produces limited and often temporary response.

OCD: Ego-Syntonic vs. Ego-Dystonic Presentations

OCD co-occurs in approximately 17–37% of autistic people — far higher than the 2–3% general population rate. The clinical challenge is distinguishing autistic repetitive behaviors and special interests from OCD compulsions and obsessions.

The key diagnostic distinction: in classic OCD, obsessions and compulsions are ego-dystonic — they feel foreign, intrusive, and distressing to the person, who recognizes them as senseless but cannot stop. In autism, repetitive behaviors (stimming, rigid routines, intense interests) are often ego-syntonic — they feel natural, self-regulating, and meaningful. The autistic person does not experience their routine as an unwanted compulsion; they experience it as a genuine need. Misdiagnosing these as OCD and applying ERP-based response prevention to autistic regulatory behaviors can cause genuine harm.

PTSD and Complex Trauma

Autistic people experience significantly higher rates of traumatic events — including bullying, abuse, medical trauma, ABA (Applied Behavior Analysis) therapy with coercive elements, and the chronic stress of navigating masking in environments not built for autistic brains. C-PTSD is common in late-diagnosed autistic adults who spent decades being told their natural responses were wrong, inappropriate, or “too much.”

Eating Disorders in Autistic Women

Research has found disproportionately high rates of autism in people with anorexia nervosa — some studies suggest 20–35% of anorexia patients meet autism criteria. ARFID (Avoidant/Restrictive Food Intake Disorder) is strongly linked to autism's sensory processing differences. The mechanisms are complex and include: sensory sensitivities around food texture and smell, rigidity and routine-seeking applied to eating, alexithymia making hunger and fullness cues harder to identify, and the perfectionism and control-seeking that accompany anxiety in autism.

The masking phenomenon creates a clinical paradox: the more effectively someone masks, the harder it is to recognize the autism underlying the presentation — and the more likely they are to be diagnosed with conditions that share surface symptoms.

• BPD misdiagnosis — Autistic emotional dysregulation, meltdowns, and the experience of being fundamentally misunderstood by others can look like borderline PD's emotional lability and unstable relationships. Autistic women are disproportionately misdiagnosed with BPD. DBT may be partially helpful but misses the neurological driver; an autism framework changes both the clinical formulation and the treatment approach.
• Bipolar misdiagnosis — Autistic mood states can be dramatically influenced by sensory environment, routine disruption, and social demand — producing what looks like cycling between “high” and “low” states but is actually reactivity to changing external conditions rather than endogenous mood cycling. Misdiagnosis with bipolar disorder leads to mood stabilizer trials that produce limited benefit and may cause side effects.
• Treatment-resistant depression — When depression in autistic people is treated without recognizing the autism, the structural causes of depression (masking exhaustion, social isolation, lack of affirming environment) are never addressed. The SSRI modestly helps, then stops helping, and the patient presents as “treatment-resistant” when in fact the treatment never engaged the actual driver.

Sensory processing differences are one of the most pervasive features of autism and one of the most direct drivers of anxiety. Autistic brains frequently process sensory input with different thresholds — either hypersensitive (lights too bright, sounds too loud, textures intolerable) or hyposensitive (reduced awareness of pain, temperature, or proprioception) — and often both, depending on the modality.

Sensory overload is not a metaphor. It is a real physiological state in which the nervous system is flooded with stimulation it cannot adequately filter — activating the stress response, impairing executive function, and producing behavioral outputs that look like emotional dysregulation but are actually nervous system responses to an environment exceeding tolerance.

Interoception and Alexithymia

Interoception — the ability to perceive internal body states — is often impaired in autism. Many autistic people have difficulty identifying hunger, thirst, pain, fatigue, and crucially, emotional states as they are developing. This links to alexithymia — the reduced ability to identify and describe emotions — which affects approximately 50% of autistic people.

Clinically, alexithymia makes psychiatric assessment more challenging. Asking “how are you feeling?” or “what is your anxiety level on a scale of 1 to 10?” may not yield accurate information if the patient cannot reliably access their internal states. Many autistic people know they are in distress only after a meltdown has already begun — because the early warning signals were not readable to them. Symptom reporting is therefore often delayed, compressed, or expressed somatically rather than emotionally.

Autistic burnout is a state of profound physical and cognitive exhaustion, reduced tolerance for sensory and social stimulation, and loss of previously held skills — particularly social and executive function skills. It is distinct from ADHD burnout in a critical way: social masking is the primary driver, not task-demand overload.

The mechanism: autistic people who mask spend enormous sustained energy performing neurotypicality — making eye contact that does not come naturally, suppressing stimming that would provide nervous system regulation, scripting and executing social interactions that require deliberate effort rather than intuitive processing. This masking performance is metabolically expensive. When sustaining it for years without reprieve — in school, employment, relationships, medical settings — the underlying nervous system eventually reaches a threshold beyond which it can no longer sustain the performance.

Autistic burnout can include:

• Loss of the ability to mask — suddenly unable to perform the social scripts that previously came with effort
• Regression of previously held skills — difficulties with speech, self-care, and executive function that were previously functional
• Extreme sensory sensitivity — unable to tolerate environments previously manageable
• Social withdrawal and need for extensive recovery time after any interaction
• Cognitive shutdown — inability to process information, make decisions, or initiate tasks

This presentation closely mimics severe MDD — withdrawal, cognitive impairment, loss of function, exhaustion. The critical difference: antidepressants alone do not resolve autistic burnout, because they do not address the masking demand structure. Recovery requires reduction in the masking load, increased access to autistic community and identity affirmation, and removal from environments requiring sustained performance. Recovery timelines are often 6–12 months minimum.

There is no medication for autism itself. The medications used in autistic people target co-occurring conditions — anxiety, depression, ADHD, OCD, sleep disturbances, emotional dysregulation — and they require adjustment because autism changes how they work.

SSRIs: Start Low, Go Slow

SSRIs are frequently prescribed for anxiety and OCD in autistic people, but they carry a specific risk: many autistic individuals experience behavioral activation — increased agitation, impulsivity, insomnia, and paradoxical worsening of anxiety — at doses that would be well-tolerated in neurotypical patients. The mechanism is not fully understood but may relate to differences in serotonin receptor sensitivity.

Stimulants for ADHD Co-Occurrence

Stimulants are effective for the ADHD component of AuDHD and are generally used at standard doses. However, autistic people with sensory sensitivities may experience side effects — notably anxiety, heightened sensory awareness, and emotional reactivity — more intensely than non-autistic ADHD patients. Dose titration requires attention to sensory tolerance and behavior, not just executive function improvement.

Clonidine and Guanfacine for Emotional Dysregulation

Alpha-2 agonists (clonidine and guanfacine) have evidence for reducing emotional dysregulation, irritability, and hyperarousal in autism. They are particularly useful when emotional dysregulation is a significant feature and when stimulants are either contraindicated or have worsened anxiety. Guanfacine extended- release is FDA-approved for ADHD and used off-label for emotional regulation in autism.

Quetiapine Low-Dose for Sleep

Sleep disturbances are extremely common in autism — circadian rhythm dysregulation, difficulty transitioning to sleep, frequent night waking. Low-dose quetiapine (12.5–50 mg) is sometimes used off-label for sleep in autism when melatonin and sleep hygiene interventions have been insufficient. It is sedating at low doses through H1 antihistamine blockade and does not carry the same metabolic risks at these doses as at antipsychotic doses. Use should be time-limited and regularly reviewed.

“Neurodiversity-affirming” care is not a euphemism for refusing to treat mental health conditions. It is a clinical framework that distinguishes between:

• Autistic traits that are simply different ways of being (direct communication style, sensory sensitivities, special interests, stimming) — which are not targets for treatment
• Co-occurring mental health conditions (anxiety, depression, OCD, ADHD) — which are absolutely appropriate treatment targets
• Masking-driven suffering — which requires addressing the masking demand, not simply suppressing its emotional output

Affirming care rejects the goal of making autistic people appear more neurotypical. It accepts autistic communication styles, supports sensory needs rather than demanding their suppression, and frames autism as a neurological difference — not a disorder to be corrected. This is not just ethically important; it is clinically important. The research on autistic wellbeing consistently shows that acceptance of autistic identity — including self-acceptance — is one of the strongest predictors of positive mental health outcomes.

Adult autism evaluation typically involves one or more of the following instruments:

• ADOS-2 (Autism Diagnostic Observation Schedule, 2nd edition) — a semi- structured clinical observation that evaluates social communication, interaction, and restricted/repetitive behaviors. Considered the gold standard observational assessment.
• ADI-R (Autism Diagnostic Interview — Revised) — a structured caregiver/ informant interview covering developmental history. Particularly useful for accessing information about early childhood that the adult may not recall.
• RAADS-R (Ritvo Autism Asperger Diagnostic Scale — Revised) — a self-report questionnaire with strong validity for adult identification, including for high-masking individuals. Useful as a screening tool or supplement to observational assessment.

Adult autism evaluations vary significantly by setting and evaluator. A comprehensive evaluation by a psychologist with autism expertise is ideal. Waiting lists can be long (6–18 months in many areas) and costs can be high ($2,000–$4,000 out of pocket if insurance does not cover). Self-identification is recognized as valid within many autistic communities while formal diagnosis is pursued. The evaluation is important for accessing accommodations, medication adjustments, and affirming care.

If you are pursuing psychiatric care and suspect you may be autistic — especially if you have a history of treatment-resistant depression, BPD or bipolar misdiagnosis, or lifelong struggles that have never fully responded to standard treatment — these are useful things to communicate to your prescriber:

• “I have significant sensory sensitivities — lights, sounds, textures. I need you to know that when evaluating my anxiety, some of it is sensory-driven, not cognitive.”
• “I have been told throughout my life that I'm socially awkward, or that I miss social cues. I work very hard to appear neurotypical and it exhausts me.”
• “I have tried multiple SSRIs and they have either not helped or made my agitation worse. I am wondering if my neurology might be affecting how I respond to medication.”
• “I am currently pursuing an autism evaluation. While that's in process, I'd like us to consider the possibility when we make medication decisions — specifically starting at low doses and titrating slowly.”
• “I struggle to identify my emotions in the moment. I may not report distress accurately — I often only know I'm in crisis after the fact.”